Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade B 75.26 -1.09% -0.83
BPMC closed down 1.09 percent on Tuesday, February 19, 2019, on 71 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Feb 20

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BPMC trend table...

Date Alert Name Type % Chg
Feb 19 Inside Day Range Contraction 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 15 Pocket Pivot Bullish Swing Setup -1.09%
Feb 15 Overbought Stochastic Strength -1.09%
Feb 14 Stochastic Reached Overbought Strength 0.83%
Feb 14 Overbought Stochastic Strength 0.83%
Feb 12 180 Bullish Setup Bullish Swing Setup 1.06%
Feb 11 MACD Bearish Signal Line Cross Bearish 3.76%
Feb 8 Hammer Candlestick Bullish 2.90%
Feb 8 1,2,3 Pullback Bullish Bullish Swing Setup 2.90%

Older signals for BPMC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Mastocytosis Tyrosine Kinase Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 109.0
52 Week Low 44.58
Average Volume 323,888
200-Day Moving Average 67.6838
50-Day Moving Average 63.1018
20-Day Moving Average 71.8705
10-Day Moving Average 73.884
Average True Range 2.4907
ADX 38.06
+DI 27.6851
-DI 9.5041
Chandelier Exit (Long, 3 ATRs ) 69.26789999999999
Chandelier Exit (Short, 3 ATRs ) 72.87210000000001
Upper Bollinger Band 77.4332
Lower Bollinger Band 66.3078
Percent B (%b) 0.8
BandWidth 15.479787
MACD Line 3.2912
MACD Signal Line 3.4378
MACD Histogram -0.1466
Fundamentals Value
Market Cap 2.95 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -24.12
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.78
Resistance 3 (R3) 77.90 77.17 77.36
Resistance 2 (R2) 77.17 76.53 77.12 77.22
Resistance 1 (R1) 76.22 76.14 75.86 76.10 77.08
Pivot Point 75.49 75.49 75.31 75.44 75.49
Support 1 (S1) 74.54 74.85 74.18 74.42 73.44
Support 2 (S2) 73.81 74.46 73.76 73.30
Support 3 (S3) 72.86 73.81 73.16
Support 4 (S4) 72.74